Cargando…
Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors
Breast cancer patients who are HER2-positive receive targeted inhibitors to HER2, including trastuzumab and lapatinib. While patients benefit from the use of HER2 inhibitors, many fail therapy and almost all patients become resistant to treatment, indicating a critical need to prevent treatment fail...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4342830/ https://www.ncbi.nlm.nih.gov/pubmed/25515931 http://dx.doi.org/10.1007/s10549-014-3227-9 |